Medifocus, Inc. Announces Global Market Expansion with Prolieve® Performed and Reimbursed by Insurance Carriers in Hong Kong COLUMBIA, Md. and TORONTO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Medifocus, Inc. (OTCQB: MDFZF and TSXV: MFS) ("Medifocus" or the "Company"), a biotechnology company with a portfolio of medical products...

Medifocus, Inc. Announces Recent Publication Highlighting Its Focal Therapy for Prostate and Breast Cancer Treatment Initiatives COLUMBIA, Md. and TORONTO, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Medifocus, Inc. (OTCQB: MDFZF and TSXV: MFS) ("Medifocus" or the "Company"), a biotechnology company with a portfolio of medical products...

Uptick Newswire’s Stock Day Podcast Hosts Medifocus, Inc.’s CEO to Discuss Their Minimally Invasive Breakthrough Treatments for Prostate and Breast Cancers PHOENIX, Dec. 10, 2018 (GLOBE NEWSWIRE) -- The Uptick Newswire Stock Day Podcast features Medifocus, Inc. (OTCQB: MDFZF and TSXV: MFS) ("Medifocus" or the "Company"), a biotechnology company with a...

Medifocus, Inc. Announces FDA PMA Supplement Approval for New Labeling Based on Successful Completion of FDA Post Approval Study (PAS) for the Prolieve® Thermodilatation™ Device COLUMBIA, Md. and TORONTO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Medifocus, Inc. (OTCQB: MDFZF and TSXV: MFS), a biotechnology company with a portfolio of medical technologies utilizing Focused...

Medifocus Inc.’s General Manager and Medical Director Discuss Their Breakthrough Products with Uptick Newswire’s Stock Day Podcast PHOENIX, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Medifocus, Inc. (TSXV:MFS) (OTCQB: MDFZF) (“the Company”) is a Biotechnology Company with a portfolio of medical technologies that utilize patented Focal...